Literature DB >> 29631979

Penile Traction Therapy and Vacuum Erection Devices in Peyronie's Disease.

Ross A Avant1, Matthew Ziegelmann1, Avinash Nehra1, Manaf Alom1, Tobias Kohler1, Landon Trost2.   

Abstract

INTRODUCTION: Peyronie's disease (PD) has historically been managed by at least 1 treatment, including oral supplements or medications, intralesional injections, or surgery. Adjunctive mechanical therapies also have been described, including penile traction therapy (PTT) and vacuum erection devices (VEDs), although relatively limited data are available on their use with PD. AIM: To review and summarize the published literature on the role and efficacy of PTT and VED in men with PD.
METHODS: A PubMed search was performed of all publications on PTT and VED in men with PD from inception through September 2017. MAIN OUTCOME MEASURES: Changes in penile curvature, length, girth, erectile function, and adverse events with PTT or VED.
RESULTS: PTT and VED exhibit mechanisms to improve aspects of PD, although clinical outcomes data are limited. Based on current data, PTT likely has a potential role as a primary lengthening therapy (modest improvements), in curvature correction (acute phase; unclear role in chronic phase), before penile prosthesis insertion, and after surgical correction of PD. The role of PTT as a combination therapy during collagenase Clostridium histolyticum injections is unclear. Fewer and lower level-of-evidence studies are available on VEDs and suggest potential roles in curvature correction, before penile prosthesis placement, or after PD surgery. Guideline statements from the American Urological Association and International Consultation on Sexual Medicine also support the potential role of PTT and VED in managing PD.
CONCLUSIONS: PTT and VED represent viable therapeutic options for managing PD, with more data currently available on PTT. Because all PTT studies used a similar style of traction device, it is unclear whether results reflect outcomes of these particular devices or traction more broadly. Further studies are required to better delineate the benefits of PTT and VED, particularly in relation to other established treatments. Avant RA, Ziegelman M, Nehra A, et al. Penile Traction Therapy and Vacuum Erection Devices in Peyronie's Disease. Sex Med Rev 2019;7:338-348.
Copyright © 2018 International Society for Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Andropenis; Collagenase; Curvature; Length; Xiaflex

Mesh:

Year:  2018        PMID: 29631979     DOI: 10.1016/j.sxmr.2018.02.005

Source DB:  PubMed          Journal:  Sex Med Rev        ISSN: 2050-0521


  4 in total

Review 1.  Modern treatment strategies for penile prosthetics in Peyronie's disease: a contemporary clinical review.

Authors:  Matthew J Ziegelmann; M Ryan Farrell; Laurence A Levine
Journal:  Asian J Androl       Date:  2020 Jan-Feb       Impact factor: 3.285

2.  How Atypical Penile Curvature Influence Clinical Outcomes in Patients with Peyronie's Disease Receiving Collagenase Clostridium Histolyticum Therapy?

Authors:  Andrea Cocci; Fabrizio Di Maida; Giorgio Ivan Russo; Marina Di Mauro; Gianmartin Cito; Marco Falcone; Andrea Minervini; Giovanni Cacciamani; Riccardo Campi; Andrea Mari; Francesco Sessa; Nicola Mondaini
Journal:  World J Mens Health       Date:  2019-05-29       Impact factor: 5.400

3.  A Randomized, Single-Blinded Clinical Trial Evaluating the Effect of Extracorporeal Shockwave Treatment (ESWT) as Add-On Therapy to Vacuum Erectile Device on Peyronie's Disease.

Authors:  Jonas Mortensen; Sune Møller Skov-Jeppesen; Peter Bill Juul Ladegaard; Lars Lund
Journal:  Res Rep Urol       Date:  2021-09-16

Review 4.  The Use of Penile Traction Devices for Peyronie's Disease: Position Statements from the European Society for Sexual Medicine.

Authors:  Borja García-Gómez; Antonio Aversa; Manuel Alonso-Isa; Arie Parnham; Ege Can Serefoglu; Giovanni Corona; Carlo Bettocchi; Yacov Reisman; Marta Skrodzka; Javier Romero-Otero
Journal:  Sex Med       Date:  2021-07-15       Impact factor: 2.523

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.